Next Article in Journal
Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids
Next Article in Special Issue
Drug Development for Pediatric Populations: Regulatory Aspects
Previous Article in Journal
Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
Previous Article in Special Issue
Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients
Pharmaceutics 2010, 2(4), 321-338; doi:10.3390/pharmaceutics2040321
Article

Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny

1, 2, 3, 4 and 1,*
1 College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, S7N5C9, Canada 2 Toxicology Centre, University of Saskatchewan, 44 Campus Drive, Saskatoon, SK, S7N 5B3, Canada 3 Department of Veterinary Pathology, Prairie Diagnostic Services, 52 Campus Drive, University of Saskatchewan, Saskatoon, SK, S7N 5B4, Canada 4 Department of Animal and Poultry Science, University of Saskatchewan, 51 Campus Drive Saskatoon, SK, S7N 5A8, Canada
* Author to whom correspondence should be addressed.
Received: 9 September 2010 / Revised: 5 October 2010 / Accepted: 12 October 2010 / Published: 14 October 2010
View Full-Text   |   Download PDF [607 KB, uploaded 14 October 2010]   |   Browse Figures

Abstract

Significant drug-nutrient interactions are possible when drugs and nutrients share the same absorption and disposition mechanisms. During postnatal development, the outcomes of drug-nutrient interactions may change with postnatal age since these processes undergo ontogenesis through the postnatal period. Our study investigated the dependence of a significant drug-nutrient interaction (cefepime-carnitine) on the timing and duration of drug exposure relative to postnatal age. Rat pups were administered cefepime (5 mg/kg) twice daily subcutaneously according to different dosing schedules (postnatal day 1-4, 1-8, 8-11, 8-20, or 1-20). Cefepime significantly reduced serum and heart L-carnitine levels in postnatal day 1-4, 1-8 and 8-11 groups and caused severe degenerative changes in ventricular myocardium in these groups. Cefepime also altered the ontogeny of several key L-carnitine homeostasis pathways. The qualitative and quantitative changes in levels of hepatic γ-butyrobetaine hydroxylase mRNA and activity, hepatic trimethyllysine hydroxlase mRNA, intestinal organic cation/carnitine transporter (Octn) mRNA, and renal Octn2 mRNA depended on when during postnatal development the cefepime exposure occurred and duration of exposure. Despite lower levels of heart L-carnitine in earlier postnatal groups, levels of carnitine palmitoyltransferase mRNA and activity, heart Octn2 mRNA and ATP levels in all treatment groups remained unchanged with cefepime exposure. However, changes in other high energy phosphate substrates were noted and reductions in the phosphocreatine/ATP ratio were found in rat pups with normal serum L-carnitine levels. In summary, our data suggest a significant drug-nutrient transport interaction in developing neonates, the nature of which depends on the timing and duration of exposure relative to postnatal age.
Keywords: drug-nutrient interaction; ontogeny; L-carnitine; cefepime; windows of susceptibility drug-nutrient interaction; ontogeny; L-carnitine; cefepime; windows of susceptibility
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Ling, B.; Aziz, C.; Wojnarowicz, C.; Olkowski, A.; Alcorn, J. Timing and Duration of Drug Exposure Affects Outcomes of a Drug-Nutrient Interaction During Ontogeny. Pharmaceutics 2010, 2, 321-338.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert